![Bart Dzikowski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bart Dzikowski
Directeur/Membre du Conseil chez University of Zurich /Venture Capital/
Provenance du réseau au premier degré de Bart Dzikowski
Entité | Type d'entité | Industrie | |
---|---|---|---|
Oculis SA
![]() Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.
10
| Holding Company | Miscellaneous Commercial Services | 10 |
Novartis Venture Funds
![]() Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.
9
| Subsidiary | Investment Managers | 9 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Bart Dzikowski via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Priothera Ltd.
![]() Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
OCULIS HOLDING AG | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
MERUS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
Novartis Venture Funds (USA)
![]() Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investment Managers | Private Equity Investor Private Equity Investor | |
Bay City Capital LLC
![]() Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Novartis Corp.
![]() Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Adicet Therapeutics, Inc.
![]() Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of London | College/University | Graduate Degree Doctorate Degree | |
binx health, inc.
![]() binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
NESTLÉ S.A. | Food: Major Diversified | Corporate Officer/Principal | |
Priothera SAS
![]() Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer | |
École Supérieure de Biothechnologie Strasbourg | College/University | Graduate Degree | |
Imcheck Therapeutics SAS
![]() Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Amyl Therapeutics SRL
![]() Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Biotechnology | Founder | |
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Swissvention Partners GmbH | Chief Executive Officer | ||
CAPTOR THERAPEUTICS SPOLKA AKCYJNA | Pharmaceuticals: Major | Director/Board Member | |
Inflazome Ltd.
![]() Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Vivet Therapeutics SAS
![]() Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman | |
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
Okairos AG
![]() Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
MyoPowers Medical Technologies France SAS
![]() MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
DURATA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
Pathway Diagnostics Ltd.
![]() Pathway Diagnostics Ltd. Medical DistributorsDistribution Services Pathway Diagnostics Ltd. provides clinical diagnostic products and medical instrumentation services. Its products include haemostasis, autoimmune and allergy, complement system, bone and cartilage, metabolic syndrome, organ injury, oncology and toxicology. The company was founded in 1999 and is headquartered in Dorking, the United Kingdom. | Medical Distributors | Director/Board Member | |
University of Saskatchewan | College/University | Doctorate Degree | |
DuPont Pharmaceuticals Co.
![]() DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
Civitas Therapeutics, Inc.
![]() Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Biotechnology | Director/Board Member | |
ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Entasis Therapeutics, Inc.
![]() Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member | |
ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member | |
INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Pivotal Bioventure Partners Investment Advisor LLC
![]() Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Rallybio Holdings LLC
![]() Rallybio Holdings LLC Medical/Nursing ServicesHealth Services Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT. | Medical/Nursing Services | Director/Board Member | |
VAXCYTE, INC. | Biotechnology | Director/Board Member | |
Evommune, Inc.
![]() Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Plexium, Inc.
![]() Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 23 |
France | 9 |
Suisse | 8 |
Irlande | 5 |
Royaume-Uni | 3 |
Sectorielle
Health Technology | 35 |
Finance | 5 |
Consumer Services | 5 |
Health Services | 4 |
Technology Services | 2 |
Opérationnelle
Director/Board Member | 142 |
Corporate Officer/Principal | 29 |
Independent Dir/Board Member | 26 |
Private Equity Investor | 18 |
Chairman | 17 |
Relations les plus connectées
Insiders | |
---|---|
Henry Skinner | 29 |
Florent Gros | 28 |
Lionel Carnot | 27 |
Anthony Adam Rosenberg | 23 |
Reinhard Ambros | 20 |
Robert Hopfner | 20 |
Anja Koenig | 19 |
Michal Silverberg | 17 |
Árni Blöndal | 12 |
Riad Sherif | 9 |
Simon Wheeler | 9 |
David A. Weber | 9 |
Beat Steffen | 4 |
Florian Muellershausen | 4 |
Marianne Uteng | 2 |
- Bourse
- Insiders
- Bart Dzikowski
- Connexions Sociétés